Zum Inhalt springen

We would like to thank our sponsors this year for their support in making the 05th Conference of Liver Disease a reality.

Your CPLD Organising Team

Our Sponsors 2022

Albireo Pharma, Inc.

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe, Bylvay has been approved for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with global Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit

Homepage: https://albireopharma.com/

10.000,- €

Alexion Pharma Germany GmbH

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion Pharma Germany GmbH is based in Munich, Germany. Further information about Alexion can be found at:

Homepage: https://www.alexion.de/

10.000,- €


Our Science Is Changing the Way Medicine Treats DiseaseTM

Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, and OXLUMO® (lumasiran) in 2020. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

Homepage: www.alnylam.com

5.000,- €



At Mirum, our mission is to create transformative medicine for patients with rare cholestatic liver diseases and, in turn, provide hope for patients and their families.

Homepage: https://mirumpharma.com/

5.000,- €

Laboratoires CTRS

Laboratoires CTRS was founded in 2002 to develop, register and market innovative therapies targeted at orphan diseases. Within its portfolio, the company commercialises a therapy for two ultra-rare bile acid synthesis defects. CTRS is fully committed to bring new treatments and satisfy unmet medical needs for extremely small patient population with a special focus on liver disorders. It partners with the healthcare community aiming to improve patients’ standard of care. CTRS has been awarded the prestigious 2014 Prix Galien France and 2016 Prix Galien International for its product Orphacol® (cholic acid).

Homepage: https://www.ctrs.fr

3.000,- €

Astellas Pharma GmbH

Homepage: https://www.astellas.com/de/

2.000,- €

Orphalan GmbH

At Orphalan we strive to develop rare disease treatments to improve the life of patients who can often feel negleted. We believe that patients across the world who are suffering with rare diseases should have access to innovative treatment

Homepage: Home – Orphalan SA

2.000,- €

Univar Solutions B.V.

Since 2013, Univar Solutions B.V. has been the UK Marketing Authorisation Holder for Trientine Dihydrochloride 300 mg, a drug supplied for the treatment of patients with Wilson’s disease.

The company has received a centralized European Marketing Authorization for this medicine in 2019. Trientine Dihydrochloride is now available in the EU as Cufence® 200 mg

Homepage: www.univarsolutions.com

2.000,- €